Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy.
Hussain
Arif
A
Department of Medicine, University of Maryland School of Medicine, University of Maryland Greenebaum Cancer Center, Baltimore, MD 21201, USA. ahussain@som.umaryland.edu
Wu
Yin
Y
Mirmiran
Alireza
A
DiBiase
Steven
S
Goloubeva
Olga
O
Bridges
Benjamin
B
Mannuel
Heather
H
Engstrom
Christine
C
Dawson
Nancy
N
Amin
Pradip
P
Kwok
Young
Y
D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D059248:Chemoradiotherapy / Q000009:adverse effects / Q000379:methods*; D003967:Diarrhea / Q000209:etiology; D004334:Drug Administration Schedule; D006801:Humans; D007970:Leukopenia / Q000209:etiology; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D017239:Paclitaxel / Q000008:administration & dosage*; D011446:Prospective Studies; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011879:Radiotherapy Dosage; D016019:Survival Analysis; D014555:Urination Disorders / Q000209:etiology
D000726:Androgen Antagonists; D000972:Antineoplastic Agents, Phytogenic; D017430:Prostate-Specific Antigen; D017239:Paclitaxel